ストックスクリーナーアプリを入手
10.00
5.71%
0.54
プレマーケット:
10.16
0.16
+1.60%
前日終値:
$9.46
開ける：
$11
24時間の取引高:
529.72K
Relative Volume:
2.69
時価総額：
$114.27M
収益：
$26,600
当期純損益:
$-14.73M
株価収益率:
-1.466
EPS:
-6.8211
ネットキャッシュフロー:
$-8.76M
1週間 パフォーマンス:
+9.89%
1か月 パフォーマンス:
+33.51%
6か月 パフォーマンス:
+38.50%
1年 パフォーマンス:
+175.82%
1日の値動き範囲:
$8.80
$11.00
1週間の範囲:
$8.41
$11.00
52週間の値動き範囲:
$2.86
$17.40
Kazia Therapeutics Limited Adr Stock (KZIA) Company Profile
名前
Kazia Therapeutics Limited Adr
セクター
電話
01161298780088
住所
140 WICKS RD, NEW SOUTH WALES 2113, NSW
Compare KZIA vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KZIA
Kazia Therapeutics Limited Adr
|
10.00 | 114.27M | 26,600 | -14.73M | -8.76M | -6.8211 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 112.35B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.71B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 52.29B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 44.48B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 35.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kazia Therapeutics Limited Adr Stock (KZIA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-06 | 開始されました | Maxim Group | Buy |
| 2021-10-14 | 開始されました | Maxim Group | Buy |
| 2021-01-05 | 開始されました | H.C. Wainwright | Buy |
Kazia Therapeutics Limited Adr (KZIA) 最新ニュース
Kazia Therapeutics (NASDAQ: KZIA) licenses SETDB1 platform, pays $1.39M upfront - Stock Titan
Kazia (NASDAQ: KZIA) licenses SETDB1 platform, plans $6M dual-program push - Stock Titan
Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform - Bitget
Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform - Benzinga
Kazia Therapeutics (KZIA) CEO updates ADS option exercise price details - Stock Titan
KZIA Stock Price, Quote & Chart | KAZIA THERAPEUTICS-SPON ADR (NASDAQ:KZIA) - ChartMill
Kazia Therapeutics (KZIA) executive discloses multiple stock option positions - Stock Titan
95,110 ADS supplement and director exit — Kazia (NASDAQ: KZIA) - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) holder reports 1.59M ADS; 13.90% stake - Stock Titan
Alumni Capital exits KZIA holdings (KZIA) — 0 ADS as of Jan 30, 2026 - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) registers 10.7M ADSs, reports $69.46M cash - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) registers 266,666 ADSs; posts half‑year update - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) files prospectus supplement for 232,956 ADSs - Stock Titan
Kazia Therapeutics (KZIA) raises major cash despite $12.6m loss - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) director Coffey details ADS options and share stakes - Stock Titan
Kazia Therapeutics (KZIA) CEO discloses multi-million share option stakes on Form 3 - Stock Titan
Kazia Therapeutics (KZIA) VP discloses initial ADS option grants - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) files $200M shelf; $100M ATM with Leerink - Stock Titan
Maxim Group Sticks to Its Buy Rating for Quoin Pharmaceuticals (QNRX) - The Globe and Mail
Jorey Chernett holds 12.46% of Kazia Therapeutics (KZIA) ADS - Stock Titan
Ikarian Capital discloses 5.1% Kazia Therapeutics (KZIA) ADS position - Stock Titan
Dauntless Investment trims Kazia Therapeutics (KZIA) position to negligible 0.0% - Stock Titan
Kazia Therapeutics stock rises on promising nuclear PD-L1 degrader data By Investing.com - Investing.com India
Kazia Therapeutics stock rises on promising nuclear PD-L1 degrader data - Investing.com UK
Experimental cancer drug targets hidden resistance driving metastasis - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) posts early TNBC trial gains in paxalisib study - Stock Titan
Early paxalisib TNBC responses highlighted by Kazia Therapeutics (NASDAQ: KZIA) - Stock Titan
Early paxalisib TNBC data: Kazia Therapeutics (NASDAQ: KZIA) sees partial and complete responses - Stock Titan
United States shares mixed at close of trade; Dow Jones Industrial Average up 0.66% _newTouch_By Investing.com - Investing.com India
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.66% - Investing.com
Kazia Therapeutics (KZIA) resale filing details $46.5M cash boost and runway to 2028 - Stock Titan
Kazia Therapeutics Retains Nasdaq Listing After Regaining Compliance - The Globe and Mail
Kazia Therapeutics secures $46.5 million through private placement to address Nasdaq compliance - MSN
Kazia Therapeutics Secures $46.5 Million Through Private Placement to Address Nasdaq Compliance - The Globe and Mail
You might want to take a look at Kazia Therapeutics Limited ADR (KZIA) now - setenews.com
Kazia Therapeutics (NASDAQ: KZIA) expects $46.5M net from PIPE to extend cash runway - Stock Titan
Check out these key findings about Hub Cyber Security Ltd (HUBC) - setenews.com
What is Kazia Therapeutics Limited ADR (KZIA) Stock Return on Shareholders’ Capital? - Setenews
Kazia Therapeutics Limited (KZIA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Kazia Therapeutics reports immune complete response in TNBC - MSN
KZIA Shares Surge: Can This Momentum Last? - StocksToTrade
Kazia Therapeutics (KZIA) Stock Soars on Breakthrough Results in Breast Cancer Treatment - parameter.io
Kazia Therapeutics receives Nasdaq delisting notice, plans to request hearing By Investing.com - Investing.com India
Kazia Therapeutics receives Nasdaq delisting notice, plans to request hearing - Investing.com
Kazia Therapeutics Achieves Initial iCR… - digitalmore.co
Kazia reports immune-complete response in metastatic breast cancer By Investing.com - Investing.com South Africa
Kazia reports immune-complete response in metastatic breast cancer - Investing.com
Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy - The Manila Times
Kazia stock soars after patient shows complete response in TNBC trial - Investing.com Nigeria
Kazia Therapeutics Limited Adr (KZIA) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):